Page last updated: 2024-12-11
hql-79
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6540277 |
| CHEMBL ID | 574003 |
| SCHEMBL ID | 347141 |
| SCHEMBL ID | 21496196 |
| MeSH ID | M0299103 |
Synonyms (43)
| Synonym |
|---|
| 162641-16-9 |
| CC-704 , |
| hql , |
| 4-(benzhydryloxy)-1-[3-(1h-tetraazol-5-yl)propyl]piperidine |
| hql-79 , |
| 2CVD , |
| DB07917 |
| CHEMBL574003 , |
| 1-(3-(2h-tetrazol-5-yl)propyl)-4-(benzhydryloxy)piperidine |
| 1-(3-(1h-tetrazol-5-yl)propyl)-4-(benzhydryloxy)piperidine |
| bdbm50300128 |
| 4-benzhydryloxy-1-[3-(2h-tetrazol-5-yl)propyl]piperidine |
| FT-0643573 |
| AM84555 |
| gtpl6662 |
| 4-[di(phenyl)methoxy]-1-[3-(2h-tetrazol-5-yl)propyl]piperidine |
| hql79 |
| SCHEMBL347141 |
| hql 79 |
| 4-(diphenylmethoxy)-1-(3-2h-tetrazol-5-yl)propyl]-piperidine |
| DTXSID50424898 |
| TZQGXAHOROZEKN-UHFFFAOYSA-N , |
| 4-(diphenylmethoxy)-1-[3-(1h-tetrazol-5-yl)propylpiperidine |
| AKOS024457666 |
| HMS3648E13 |
| EX-A091 |
| J-009960 |
| 4-(diphenylmethoxy)-1-[3-(2h-tetrazol-5-yl)propyl]piperidine |
| NCGC00343938-06 |
| hql-97 |
| 4-(diphenylmethoxy)-1-[3-(1h-tetrazol-5-yl)propyl]piperidine |
| SCHEMBL21496196 |
| AKOS032947265 |
| BCP06026 |
| F17406 |
| Q27077992 |
| AS-16439 |
| SR-01000946205-1 |
| sr-01000946205 |
| HY-108259 |
| CS-0027831 |
| piperidine, 4-(diphenylmethoxy)-1-[3-(2h-tetrazol-5-yl)propyl]- |
| AC-36790 |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (3)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 6.0081 | 0.0010 | 8.3798 | 61.1304 | AID1645840 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Hematopoietic prostaglandin D synthase | Homo sapiens (human) | IC50 (µMol) | 26.5000 | 0.0710 | 0.9222 | 3.8000 | AID442514; AID499186; AID499201 |
| Hematopoietic prostaglandin D synthase | Homo sapiens (human) | Ki | 5.0000 | 5.0000 | 5.0000 | 5.0000 | AID1719064 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Activation Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Glutathione-requiring prostaglandin D synthase | Homo sapiens (human) | Kd | 0.8000 | 0.8000 | 0.8000 | 0.8000 | AID977611 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (6)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| prostaglandin biosynthetic process | Hematopoietic prostaglandin D synthase | Homo sapiens (human) |
| prostaglandin metabolic process | Hematopoietic prostaglandin D synthase | Homo sapiens (human) |
| signal transduction | Hematopoietic prostaglandin D synthase | Homo sapiens (human) |
| locomotory behavior | Hematopoietic prostaglandin D synthase | Homo sapiens (human) |
| negative regulation of male germ cell proliferation | Hematopoietic prostaglandin D synthase | Homo sapiens (human) |
| glutathione metabolic process | Hematopoietic prostaglandin D synthase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Molecular Functions (6)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| magnesium ion binding | Hematopoietic prostaglandin D synthase | Homo sapiens (human) |
| glutathione transferase activity | Hematopoietic prostaglandin D synthase | Homo sapiens (human) |
| prostaglandin-D synthase activity | Hematopoietic prostaglandin D synthase | Homo sapiens (human) |
| calcium ion binding | Hematopoietic prostaglandin D synthase | Homo sapiens (human) |
| protein binding | Hematopoietic prostaglandin D synthase | Homo sapiens (human) |
| protein homodimerization activity | Hematopoietic prostaglandin D synthase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Ceullar Components (4)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| nucleoplasm | Hematopoietic prostaglandin D synthase | Homo sapiens (human) |
| cytoplasm | Hematopoietic prostaglandin D synthase | Homo sapiens (human) |
| cytosol | Hematopoietic prostaglandin D synthase | Homo sapiens (human) |
| intracellular membrane-bounded organelle | Hematopoietic prostaglandin D synthase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Bioassays (19)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID499198 | Cytotoxicity against human MEG-01S cells assessed as reduction in cell viability after 24 hrs by MTT assay | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Development and characterization of new inhibitors of the human and mouse hematopoietic prostaglandin D(2) synthases. |
| AID499186 | Inhibition of human H-PGDS expressed in Escherichia coli BL21 DE2 by enzyme immuno assay | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Development and characterization of new inhibitors of the human and mouse hematopoietic prostaglandin D(2) synthases. |
| AID499201 | Inhibition of human H-PGDS expressed in Escherichia coli BL21 DE2 by enzyme immuno assay at 50 uM | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Development and characterization of new inhibitors of the human and mouse hematopoietic prostaglandin D(2) synthases. |
| AID499192 | Inhibition of H-PGDH in mouse BMDM cells assessed as inhibition of LPS-stimulated TXB2 production after 24 hrs by EIA | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Development and characterization of new inhibitors of the human and mouse hematopoietic prostaglandin D(2) synthases. |
| AID1719064 | Competitive inhibition of human HPGDS using PGH2 as substrate | |||
| AID499191 | Inhibition of H-PGDH in mouse BMDM cells assessed as inhibition of LPS-stimulated 6Keto PGF1alpha production after 24 hrs by EIA | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Development and characterization of new inhibitors of the human and mouse hematopoietic prostaglandin D(2) synthases. |
| AID499190 | Inhibition of H-PGDH in mouse BMDM cells assessed as inhibition of LPS-stimulated PGE2 production after 24 hrs by EIA | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Development and characterization of new inhibitors of the human and mouse hematopoietic prostaglandin D(2) synthases. |
| AID442514 | Inhibition of human H-PGDS expressed in Escherichia coli BL21 assessed as rate of glutathione-chloro-dinitro benzene conjugation | 2010 | European journal of medicinal chemistry, Feb, Volume: 45, Issue:2 | Identification and characterisation of new inhibitors for the human hematopoietic prostaglandin D2 synthase. |
| AID499197 | Inhibition of H-PGDH in human MEG-01S cells assessed as inhibition of A-23187-stimulated PGD2 production at 100 uM after 24 hrs by EIA | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Development and characterization of new inhibitors of the human and mouse hematopoietic prostaglandin D(2) synthases. |
| AID499189 | Cytotoxicity against mouse BMDM cells assessed as reduction in cell viability at 100 uM after 24 hrs by MTT assay | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Development and characterization of new inhibitors of the human and mouse hematopoietic prostaglandin D(2) synthases. |
| AID442515 | Inhibition of human H-PGDS expressed in Escherichia coli BL21 assessed as rate of glutathione-chloro-dinitro benzene conjugation at 50 uM | 2010 | European journal of medicinal chemistry, Feb, Volume: 45, Issue:2 | Identification and characterisation of new inhibitors for the human hematopoietic prostaglandin D2 synthase. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1345296 | Human H-PGDS (Prostaglandin synthases) | 2006 | The Journal of biological chemistry, Jun-02, Volume: 281, Issue:22 | Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase. |
| AID977611 | Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB | 2006 | The Journal of biological chemistry, Jun-02, Volume: 281, Issue:22 | Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase. |
| AID1811 | Experimentally measured binding affinity data derived from PDB | 2006 | The Journal of biological chemistry, Jun-02, Volume: 281, Issue:22 | Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 17.61
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.61) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||